
CellCarta and Imagene AI Scale AI-Driven Companion Diagnostics
By integrating Imagene’s AI pathology models with CellCarta’s global laboratory infrastructure, the two companies are creating a standardized pathway for pharmaceutical firms to validate and deploy biomarker-based diagnostic programs, moving beyond experimental algorithms into the rigorous demands of large-scale clinical trials and regulatory approval.



























